science_technology_and_other_research_and_development · DOD-AMRAA

DoW Toxic Exposures Clinical Trial Award

Defense Health Agency Contracting Activity - DHACA · HT942526TERPCTA

90 days left

Total Program Funding

$4.5M

Expected Awards

Deadline

November 19, 2026

GRANTQUICK SUMMARYPlain-English Overview

DoD Toxic Exposures Research Program Clinical Trial Award — single award for a clinical trial addressing health effects of military toxic exposures (burn pits, PFAS, Agent Orange, radiation).

Who Should Apply

Clinical researchers with capacity to conduct trials on health conditions caused by military toxic exposures.

Who Should NOT Apply

Basic science researchers, non-clinical investigators.

Key Requirements (Plain English)

•Must conduct clinical trial on toxic exposure effects
•Single award
•Must address military exposures

💡 GrantQuick Tip

PACT Act has elevated toxic exposure research. Propose trials on burn pit-related respiratory disease, PFAS-related cancers, or interventions for exposed veterans.

Competitiveness: Very high — single award.

What This Grant Funds

Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations.

Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts.

https://cdmrp.health.mil/pubs/press/2026/terppreann